Medicine and Dentistry
Antiretroviral Therapy
100%
Human Immunodeficiency Virus
62%
Therapeutic Procedure
60%
Patient
43%
Combination Therapy
42%
Cell Count
40%
Adult
34%
Placebo
29%
Cells
28%
Bone Density
27%
Human Immunodeficiency Virus Infection
25%
COVID-19
23%
Death
23%
Person
21%
Follow up
20%
Cardiovascular Disease
18%
Amaurosis
18%
Inpatient
17%
Drug
17%
Chemotherapeutic Agent
17%
Disease
15%
Arm
15%
T-Helper Cell
14%
Monitoring
13%
Osteolysis
12%
Health
12%
Vaccine
11%
Hazard Ratio
11%
Spine
9%
Age
9%
Ebolavirus
9%
Virus RNA
8%
Group Therapy
8%
Task Performance
8%
Proportional Hazards Model
8%
Hip
8%
Treatment Interruption
7%
Virus Infection
7%
D-Dimer
7%
Assessment
7%
Abdominal Fat
7%
Biological Marker
7%
Computer Assisted Tomography
7%
Measurement
7%
Randomized Controlled Trial
7%
Monoclonal Antibody
6%
Predictor
6%
RNA
6%
Hospital
6%
Serositis
6%
Nursing and Health Professions
Antiretroviral Therapy
56%
Combination Therapy
26%
CD4 Lymphocyte Count
18%
Bone Density
17%
Quality of Life
12%
Human Immunodeficiency Virus Infection
12%
Odds Ratio
9%
Confidence Interval
9%
Placebo
8%
Follow up
8%
Patient
8%
Drug
7%
Death
7%
Analysis
6%
Diseases
6%
Adult
6%
Blindness
6%
Body Composition
6%
Monoclonal Antibody
6%
Receiver Operating Characteristic
5%
Prevention
5%
Metabolic Parameters
5%
Cost Effectiveness Analysis
5%
Biological Marker
5%
Treatment Interruption
5%
Heart Muscle Ischemia
5%
Ischemic Heart Disease
5%
Fat
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
23%
Blindness
18%
Vaccine
13%
Monoclonal Antibody
12%
Diseases
12%
Placebo
9%
Death
9%
SARS Coronavirus
7%
Human Immunodeficiency Virus Infection
7%
Ebola Virus Disease
7%
Drug
7%
Coronavirinae
6%
Antivirus Agent
6%
Acquired Immune Deficiency Syndrome
6%
Circulating microRNA
5%
Inflammation
5%
Ebola Hemorrhagic Fever
5%
Normal Human
5%
Hyperimmune Globulin
5%
Biological Marker
5%
Dioxygenase
5%
